2007

Capital Royalty Acquires Interest in One of the Largest Oncology Drugs in the Market

Capital Royalty worked closely with the royalty holder and its advisors to structure a transaction that provided in excess of $100 million in exchange for an interest in the royalty stream of the oncology drug’s revenues. Capital Royalty worked with a co-investor to facilitate funding the entire transaction at close.